Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Appl Physiol (1985) ; 114(6): 752-60, 2013 Mar 15.
Article in English | MEDLINE | ID: mdl-23349456

ABSTRACT

Nitric oxide (NO) exerts a wide range of cellular effects in the cardiovascular system. NO is short lived, but S-nitrosoglutathione (GSNO) functions as a stable intracellular bioavailable NO pool. Accordingly, increased levels can facilitate NO-mediated processes, and conversely, catabolism of GSNO by the regulatory enzyme GSNO reductase (GSNOR) can impair these processes. Because dysregulated GSNOR can interfere with processes relevant to cardiovascular health, it follows that inhibition of GSNOR may be beneficial. However, the effect of GSNOR inhibition on vascular activity is unknown. To study the effects of GSNOR inhibition on endothelial function, we treated rats with a small-molecule inhibitor of GSNOR (N6338) that has vasodilatory effects on isolated aortic rings and assessed effects on arterial flow-mediated dilation (FMD), an NO-dependent process. GSNOR inhibition with a single intravenous dose of N6338 preserved FMD (15.3 ± 5.4 vs. 14.2 ± 6.3%, P = nonsignificant) under partial NO synthase inhibition that normally reduces FMD by roughly 50% (14.1 ± 2.9 vs. 7.6 ± 4.4%, P < 0.05). In hypertensive rats, daily oral administration of N6338 for 14 days reduced blood pressure (170.0 ± 5.3/122.7 ± 6.4 vs. 203.8 ± 1.9/143.7 ± 7.5 mmHg for vehicle, P < 0.001) and vascular resistance index (1.5 ± 0.4 vs. 3.2 ± 1.0 mmHg · min · l(-1) for vehicle, P < 0.001), and restored FMD from an initially impaired state (7.4 ± 1.7%, day 0) to a level (13.0 ± 3.1%, day 14, P < 0.001) similar to that observed in normotensive rats. N6338 also reversed the pathological kidney changes exhibited by the hypertensive rats. GSNOR inhibition preserves FMD under conditions of impaired NO production and protects against both microvascular and conduit artery dysfunction in a model of hypertension.


Subject(s)
Aldehyde Oxidoreductases/antagonists & inhibitors , Antihypertensive Agents/pharmacology , Endothelium, Vascular/drug effects , Enzyme Inhibitors/pharmacology , Femoral Artery/drug effects , Hypertension/drug therapy , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Administration, Oral , Aldehyde Oxidoreductases/metabolism , Animals , Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Cells, Cultured , Disease Models, Animal , Dose-Response Relationship, Drug , Endothelium, Vascular/enzymology , Endothelium, Vascular/physiopathology , Enzyme Inhibitors/administration & dosage , Femoral Artery/enzymology , Femoral Artery/physiopathology , Humans , Hypertension/enzymology , Hypertension/etiology , Hypertension/pathology , Hypertension/physiopathology , Injections, Intravenous , Kidney/drug effects , Kidney/pathology , Mice , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/antagonists & inhibitors , Nitric Oxide Synthase Type III/metabolism , Rats , Rats, Inbred Dahl , Rats, Sprague-Dawley , Sodium Chloride, Dietary , Time Factors , Vasodilator Agents/administration & dosage
2.
Biochem Biophys Res Commun ; 409(4): 758-63, 2011 Jun 17.
Article in English | MEDLINE | ID: mdl-21621512

ABSTRACT

Uremic toxins such as indoxyl sulfate (IS) accumulate at a high level in end stage renal disease (ESRD) and can exhibit significant systemic endothelial toxicity leading to accelerated cardiovascular events. The precise molecular mechanisms by which IS causes endothelial dysfunction are unknown. We tested the hypothesis that IS negatively influences properties of endothelial cells, such as migration and tube formation, by depleting nitric oxide (NO) bioavailability, and that an NO donor can reverse these inhibitory effects. IS inhibited human umbilical vein endothelial cell (HUVEC) migration and formation of tubes on matrigel. Mechanistically, IS inhibited VEGF-induced NO release from HUVECs. An NO donor, SNAP, reversed IS-mediated inhibition of HUVEC migration as well as tube-formation. IS inhibited ERK 1/2 MAP kinase activity in a dose-dependent manner, but this was preserved by SNAP. Inhibition of ERK 1/2 with a pharmacological inhibitor (U0126) decreased HUVEC migration and tube formation; these effects too were prevented by SNAP. Further, IS stimulated activation of myosin light chain (MLC), potentially stimulating endothelial contractility, while SNAP decreased MLC activation. Thus, we conclude that the negative effects of IS on endothelial cells are prevented, to a major extent, by NO, via its divergent actions on ERK MAP kinase and MLC.


Subject(s)
Cell Movement/drug effects , Endothelial Cells/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Indican/antagonists & inhibitors , Myosin Light Chains/metabolism , Nitric Oxide/metabolism , Uremia/metabolism , Cells, Cultured , Endothelial Cells/metabolism , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Humans , Indican/metabolism , Indican/toxicity , Myosin Light Chains/antagonists & inhibitors , Nitric Oxide Donors/pharmacology , S-Nitroso-N-Acetylpenicillamine/pharmacology
3.
BMC Syst Biol ; 1: 9, 2007 Jan 29.
Article in English | MEDLINE | ID: mdl-17408516

ABSTRACT

BACKGROUND: Computational models of cell signaling networks typically are aimed at capturing dynamics of molecular components to derive quantitative insights from prior experimental data, and to make predictions concerning altered dynamics under different conditions. However, signaling network models have rarely been used to predict how cell phenotypic behaviors result from the integrated operation of these networks. We recently developed a decision tree model for how EGF-induced fibroblast cell motility across two-dimensional fibronectin-coated surfaces depends on the integrated activation status of five key signaling nodes, including a proximal regulator of transcellular contractile force generation, MLC (myosin light chain) [Hautaniemi et al, Bioinformatics 21: 2027 {2005}], but we have not previously attempted predictions of new experimental effects from this model. RESULTS: In this new work, we construct an improved decision tree model for the combined influence of EGF and fibronectin on fibroblast cell migration based on a wider spectrum of experimental protein signaling and cell motility measurements, and directly test a significant and non-intuitive a priori prediction for the outcome of a targeted molecular intervention into the signaling network: that partially reducing activation of MLC would increase cell motility on moderately adhesive surfaces. This prediction was indeed confirmed experimentally: partial inhibition of the activating MLC kinase (MLCK) upstream using the pharmacologic agent ML-7 resulted in increased motility of NR6 fibroblasts. We further extended this exciting finding by showing that partial reduction of MLC activation similarly enhanced the transmigration of the human breast carcinoma cell line MDA-213 through a Matrigel barrier. CONCLUSION: These findings specifically highlight a central regulatory role for transcellular contractility in governing cell motility, while at the same time demonstrating the value of a decision tree approach to a systems "signal-response" model in discerning non-intuitive behavior arising from integrated operation a cell signaling network.


Subject(s)
Cell Movement , Computer Simulation , Decision Trees , Fibroblasts/physiology , Models, Biological , Myosin-Light-Chain Kinase/physiology , Signal Transduction , Azepines/pharmacology , Cell Line , Cell Movement/drug effects , Cell Movement/genetics , Epidermal Growth Factor/genetics , Epidermal Growth Factor/pharmacology , Epidermal Growth Factor/physiology , Fibroblasts/drug effects , Fibroblasts/enzymology , Fibronectins/genetics , Fibronectins/pharmacology , Fibronectins/physiology , Humans , Myosin-Light-Chain Kinase/antagonists & inhibitors , Naphthalenes/pharmacology , Protein Kinase Inhibitors/pharmacology
4.
Biochem Biophys Res Commun ; 343(3): 848-56, 2006 May 12.
Article in English | MEDLINE | ID: mdl-16564022

ABSTRACT

Tumor progression to the invasive phenotype occurs secondary to upregulated signaling from growth factor receptors that drive key cellular responses like proliferation, migration, and invasion. We hypothesized that Protein kinase Cdelta (PKCdelta)-mediated transcellular contractility is required for migration and invasion of prostate tumor cells. Two invasive human prostate cancer cell lines, DU145 cells overexpressing wildtype human EGFR (DU145WT) and PC3 cells, were studied. PKCdelta is overexpressed in these cells relative to normal prostate epithelial cells, and is activated downstream of EGFR leading to cell motility via modulation of myosin light chain activity. Abrogation of PKCdelta using Rottlerin and specific siRNA significantly decreased migration and invasion of both cell lines in vitro. Both PKCdelta and phosphorylated PKCdelta protein levels were higher in human prostate cancer tissue relative to normal donor prostate as assessed by Western blotting and immunohistochemistry. Thus, we conclude that PKCdelta inhibition can limit migration and invasion of prostate cancer cells.


Subject(s)
Cell Movement , ErbB Receptors/metabolism , Prostatic Neoplasms/enzymology , Protein Kinase C-delta/metabolism , Carcinoma/enzymology , Cell Line, Tumor , Cell Movement/drug effects , Epidermal Growth Factor/pharmacology , Humans , Male , Myosin Light Chains/metabolism , Neoplasm Invasiveness , Prostatic Neoplasms/pathology , Prostatic Neoplasms/physiopathology , Signal Transduction
5.
Bioinformatics ; 21(9): 2027-35, 2005 May 01.
Article in English | MEDLINE | ID: mdl-15657095

ABSTRACT

MOTIVATION: Signal transduction cascades governing cell functional responses to stimulatory cues play crucial roles in cell regulatory systems and represent promising therapeutic targets for complex human diseases. however, mathematical analysis of how cell responses are governed by signaling activities is challenging due to their multivariate and non-linear nature. diverse computational methods are potentially available, but most are ineffective for protein-level data that is limited in extent and replication. RESULTS: We apply a decision tree approach to analyze the relationship of cell functional response to signaling activity across a spectrum of stimulatory cues. as a specific example, we studied five intracellular signals influencing fibroblast migration under eight conditions: four substratum fibronectin levels and presence versus absence of epidermal growth factor. we propose techniques for preprocessing and extending the experimental measurement set via interpolative modeling in order to gain statistical reliability. for this specific case study, our approach has 70% overall classification accuracy and the decision tree model reveals insights concerning the combined roles of the various signaling activities in governing cell migration speed. we conclude that decision tree methodology may facilitate elucidation of signal-response cascade relationships and generate experimentally testable predictions, which can be used as directions for future experiments.


Subject(s)
Algorithms , Cell Movement/physiology , Decision Support Techniques , Extracellular Matrix Proteins/metabolism , Gene Expression Regulation/physiology , Models, Biological , Signal Transduction/physiology , Animals , Computer Simulation , Logistic Models , Mice , NIH 3T3 Cells
6.
Exp Cell Res ; 299(1): 91-100, 2004 Sep 10.
Article in English | MEDLINE | ID: mdl-15302576

ABSTRACT

Tumor cell motility and invasion have been linked to upregulated signaling from both the epidermal growth factor receptor (EGFR) and that for urokinase-type plasminogen activator (uPAR). However, we do not know whether these events are interdependent or unrelated, despite the obvious diagnostic and therapeutic implications. Gene microarray analyses have suggested that EGFR signaling via phospholipase C-gamma (PLCgamma) induces uPAR transcription. We utilized two sublines of the DU145 human prostate carcinoma cell line that are genetically engineered to differentially activate the EGFR/PLCgamma cascade and are variously invasive in vitro and in vivo. uPAR protein levels in these cells were found to be dependent on PLC signaling, pharmacologic inhibition of PLC signaling reduced uPAR expression. To determine whether uPAR was a required element in EGFR-mediated invasion, we stably expressed uPAR cDNA in either sense or antisense orientation in the two DU145 sublines. Interestingly, uPA production was modulated in parallel, although to a lesser degree, with uPAR in these sublines. Antisense to uPAR significantly restricted invasion of the highly invasive DU145 WT cells through Matrigel and reduced aggressiveness of tumors in nude mice. Up-regulation of uPAR significantly increased the invasiveness of the moderately invasive DU145 parental (DU145 P) cells through Matrigel, but this increased invasiveness was not seen in mice. uPA activity appears to contribute to invasiveness at least through Matrigel, as antibody to uPA or amiloride limited the transmigration. These results support a model of tumor invasion promoted by autocrine EGFR signaling involving reinforcing altered gene expression, of uPAR at least, that further induces cell motility. Herein, a number of key molecules whose expression levels are interrelated, including both EGFR and uPAR, are required but none are sufficient in the absence of other keys molecules in promoting tumor progression.


Subject(s)
Carcinoma/metabolism , ErbB Receptors/metabolism , Neoplasm Invasiveness/genetics , Prostatic Neoplasms/metabolism , Receptors, Cell Surface/metabolism , Amiloride/pharmacology , Animals , Antisense Elements (Genetics)/pharmacology , Autocrine Communication/genetics , Carcinoma/genetics , Cell Movement/genetics , DNA, Complementary/genetics , DNA, Complementary/metabolism , Down-Regulation/drug effects , Down-Regulation/genetics , Epidermal Growth Factor/metabolism , Gene Expression Regulation, Neoplastic/genetics , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Phospholipase C gamma , Prostatic Neoplasms/genetics , Receptors, Cell Surface/genetics , Receptors, Urokinase Plasminogen Activator , Signal Transduction/drug effects , Signal Transduction/genetics , Type C Phospholipases/antagonists & inhibitors , Type C Phospholipases/metabolism , Up-Regulation/genetics , Urokinase-Type Plasminogen Activator/metabolism , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...